Display options
Cite
Rowe WJ. Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years. Int J Nephrol Renovasc Dis. 2010;3:123-7doi: 10.2147/IJNRD.S13032.
Rowe, W. J. (2010). Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years. International journal of nephrology and renovascular disease, 3123-7. https://doi.org/10.2147/IJNRD.S13032
Rowe, William J. "Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years." International journal of nephrology and renovascular disease vol. 3 (2010): 123-7. doi: https://doi.org/10.2147/IJNRD.S13032
Rowe WJ. Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years. Int J Nephrol Renovasc Dis. 2010;3:123-7. doi: 10.2147/IJNRD.S13032. Epub 2010 Sep 07. PMID: 21694938; PMCID: PMC3108772.
Copy Download .nbib Format: NLM
Share it on

Int J Nephrol Renovasc Dis. 2010;3:123-7. doi: 10.2147/IJNRD.S13032. Epub 2010 Sep 07.

Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years.

International journal of nephrology and renovascular disease

William J Rowe

Affiliations

  1. Medical University of Ohio, Toledo, OH, USA. [email protected]

PMID: 21694938 PMCID: PMC3108772 DOI: 10.2147/IJNRD.S13032

Abstract

Since pharmaceuticals cannot be used in space until liver and kidney dysfunctions are corrected, and with invariable malabsorption, it appears there is no alternative other than to use subcutaneous magnesium (Mg) replacements in the presence of deficiencies and use of gene therapy. I suggest beginning with the correction of as many as four gene deficiencies: atrial natriuretic peptide (ANP), nitric oxide (NO), vascular endothelial growth factor (VEGF), and erythropoietin (EPO), all as well as Mg related to perfusion and angiogenesis. There is no evidence of significant lunar radiation levels in the absence of a solar storm. It could then be determined whether this has resulted in correction of liver and kidney dysfunction. If this persists, serial additions of gene therapy will be required determining the effect of each individual gene trial on organ function. Microgravity and endothelial gaps with leaks trigger reduced plasma volume. Partial correction by use of a plasma volume substitute and development of a delivery device may reduce complexity of gene therapy. Research would be conducted both on Earth and in microgravity, with the development of subcutaneous pharmaceuticals and Mg, and a space walk-reliable subcutaneous silicon device, given that no replenishable subcutaneous device is presently available. A three-pronged approach provides a plan for the next 50 years: A. complete correction of a Mg deficit; B. partial replacement with plasma volume substitutes, and C. multiple gene factor strategy.

2010 Halvorson et al, publisher and licensee Dove Medical Press Ltd.

Keywords: gene therapy; kidneys; liver; magnesium; malabsorption; microgravity; space flight

References

  1. Acta Astronaut. 1997 May;40(10):719-22 - PubMed
  2. J Gravit Physiol. 2000 Jul;7(2):P67-8 - PubMed
  3. Front Biosci. 2005 May 01;10:1177-82 - PubMed
  4. Am J Cardiol. 2010 Apr 15;105(8):1203-4 - PubMed
  5. Am J Med. 2009 Nov;122(11):e1 - PubMed
  6. Hum Gene Ther. 1997 Nov 1;8(16):1881-9 - PubMed
  7. Exp Mol Med. 2004 Aug 31;36(4):336-44 - PubMed
  8. Microcirculation. 1999 Mar;6(1):7-22 - PubMed
  9. Physiol Res. 2001;50(1):83-90 - PubMed
  10. Circulation. 1998 Jan 6-13;97(1):119-20 - PubMed
  11. Semin Nephrol. 2005 Nov;25(6):379-87 - PubMed
  12. Spine (Phila Pa 1976). 2009 Dec 15;34(26):E952-8 - PubMed
  13. J Pharm Pharmacol. 2008 Aug;60(8):999-1017 - PubMed
  14. Int J Nephrol Renovasc Dis. 2009;2:51-7 - PubMed
  15. Fed Proc. 1976 Nov;35(13):2480-5 - PubMed
  16. Cardiovasc Res. 2001 Feb 16;49(3):532-42 - PubMed
  17. J Am Coll Nutr. 2004 Oct;23(5):525S-528S - PubMed
  18. Cardiovasc Res. 2008 Sep 1;79(4):549-50 - PubMed
  19. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13789-94 - PubMed
  20. N Engl J Med. 2009 Jan 29;360(5):518-21 - PubMed
  21. Aerosp Med. 1974 Sep;45(9):1046-57 - PubMed
  22. Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H778-86 - PubMed
  23. Lancet. 1992 Sep 19;340(8821):712-4 - PubMed
  24. Bull World Health Organ. 1983;61(1):7-22 - PubMed
  25. Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3404-9 - PubMed

Publication Types